These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 6137850)
21. Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Tan YL; Zhou DF; Zhang XY Schizophr Res; 2005 May; 74(2-3):263-70. PubMed ID: 15722005 [TBL] [Abstract][Full Text] [Related]
22. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation. Davidson M; Kahn RS; Powchik P; Warne P; Losonczy MF; Kaminsky R; Apter S; Jaff S; Davis KL Arch Gen Psychiatry; 1991 Jan; 48(1):73-6. PubMed ID: 1670618 [TBL] [Abstract][Full Text] [Related]
23. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease. Newcomer JW; Riney SJ; Vinogradov S; Csernansky JG Psychopharmacol Bull; 1992; 28(1):101-7. PubMed ID: 1609034 [TBL] [Abstract][Full Text] [Related]
24. Tardive dyskinesia in outpatients on depot phenothiazine. Neehall J West Indian Med J; 1989 Dec; 38(4):228-33. PubMed ID: 2576166 [TBL] [Abstract][Full Text] [Related]
32. The role of parkinsonism and antiparkinsonian therapy in the subsequent development of tardive dyskinesia. Elliott KJ; Lewis S; el-Mallakh RS; Looney SW; Caudill R; Bacani-Oropilla T Ann Clin Psychiatry; 1994 Sep; 6(3):197-203. PubMed ID: 7881501 [TBL] [Abstract][Full Text] [Related]
34. A survey of tardive dyskinesia in psychiatric inpatients in Japan. Koshino Y; Madokoro S; Ito T; Horie T; Mukai M; Isaki K Clin Neuropharmacol; 1992 Feb; 15(1):34-43. PubMed ID: 1349507 [TBL] [Abstract][Full Text] [Related]
35. Serum neuroleptic concentrations and tardive dyskinesia. Jeste DV; Linnoila M; Wagner RL; Wyatt RJ Psychopharmacology (Berl); 1982; 76(4):377-80. PubMed ID: 6126895 [TBL] [Abstract][Full Text] [Related]
36. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study. Ganzini L; Heintz RT; Hoffman WF; Casey DE Arch Gen Psychiatry; 1991 Mar; 48(3):259-63. PubMed ID: 1671743 [TBL] [Abstract][Full Text] [Related]
37. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. Glazer WM; Morgenstern H; Doucette JT J Clin Psychiatry; 1993 Apr; 54(4):133-9. PubMed ID: 8098030 [TBL] [Abstract][Full Text] [Related]
38. Comparison of severe and mild tardive dyskinesia: implications for etiology. Gardos G; Cole JO; Schniebolk S; Salomon M J Clin Psychiatry; 1987 Sep; 48(9):359-62. PubMed ID: 2887550 [TBL] [Abstract][Full Text] [Related]
39. Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients. Richardson MA; Haugland G; Craig TJ Am J Psychiatry; 1991 Oct; 148(10):1322-8. PubMed ID: 1680296 [TBL] [Abstract][Full Text] [Related]